Pharmacyclics, Inc. (PCYC: Quote) announced updated results from two clinical trials of Bruton's tyrosine kinase, or BTK, inhibitor, ibrutinib (PCI-32765), for treating patients with chronic lymphocytic leukemia, or CLL,/small lymphocytic lymphoma, or SLL.
The ibrutinib clinical updates released in two oral presentations include - 1) updated safety and efficacy data from the Phase Ib/II CLL/SLL single agent trial (PCYC-1102); and 2) updated safety and efficacy data from the Phase Ib/II CLL/SLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108).
Updated results of PCYC-1102 trial showed that the BTK inhibitor Ibrutinib (PCI-32765) is highly active and tolerable in relapsed or refractory and treatment naive chronic lymphocytic leukemia patients.
In PCYC-1108, 37% were considered refractory to a purine analog containing regimen and 13% refractory to bendamustine. There have been no discontinuations due to adverse events. With a median follow up of 8.1 months, only 2 patients have reported progressive disease and an additional 5 patients have proceeded to stem cell transplant, 23 (77%) of patients remain on study.
Click here to receive FREE breaking news email alerts for PHARMACYCLICS INC and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News